Therapeutic potential of humanized anti-interleukin-6 receptor antibody: Antitumor activity in xenograft model of multiple myeloma

Anticancer Research

Volumn 16, Issue 5 A, 1996, Pages 2537-2544

  Tsunenari, Toshiaki ^a   Akamatsu, Ken Ichi ^a   Kaiho, Shin Ichi ^a   Sato, Koh ^a   Tsuchiya, Masayuki ^a   Koishihara, Yasuo ^a   Kishimoto, Tadamitsu ^b   Ohsugi, Yoshiyuki ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Antitumor; Humanized antibody; IL 6; Multiple myeloma; Xenograft model

Indexed keywords

IMMUNOGLOBULIN G1; INTERLEUKIN 6 RECEPTOR; RECEPTOR ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; HISTOPATHOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIPLE MYELOMA; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-6; RECOMBINANT PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0029964846     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Diure BGM and Salmon SE: A clinical staging system for multiple myeloma. Cancer 36: 842-854, 1975.
2. Kyle RA: Newer approaches to the therapy of multiple myeloma. Blood 76: 1678-1679, 1990.
3. Kyle RA: Why better prognostic factors for multiple myeloma are needed. Blood 83: 1713-1716, 1994.
4. Klein B: Growth factors in human multiple myeloma. In: Cytokines in human multiple myeloma (Klein B, ed). Austin, R.G. Landes Company, 1994, pp 47-74.
5. Kishimoto T: The biology of interleukin-6. Blood 74: 1-10, 1989.
6. Hirano T, Akira S, Taga T and Kishimoto T: Biological and clinical aspects of interleukin-6. Immunol Today 11: 443-449, 1990.
7. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsudo T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi T and Kishimoto T: Complementary DNA for novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324: 73-76, 1986.
8. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A and Kishimoto T: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85, 1988.
9. Okuno Y, Takahashi T, Suzuki A, Ichiba S, Nakamura K, Fukumoto M, Okada T, Okada H and Imura H: Establishment and characterization of four myeloma cell lines which are responsive to interleukin-6 for their growth. Leukemia 5: 585-591, 1991.
10. Shimizu S, Yoshioka R, Hirose Y, Sugai S, Tachibana J and Konda S: Establishment of two interleukin-6 (B cell stimulatory factor / interferon ß2)-dependent human bonemarrow-derived myeloma cell lines. J Exp Med 169: 339-334, 1989.
11. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R and Klein B: Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83: 3654-3663, 1994.
12. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M and Bataille R: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73: 517-526 1989.
13. Goto H, Shimazaki C, Tatsumi T, Yamagata N, Hirata T, AshiharaE, Oku N, Inaba T, Fujita N, Koishihara Y, Ohsugi Y and Nakagawa M: Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro. Jpn J Cancer Res 85: 958-965, 1994.
14. Suzuki H, Yasukawa K, Saito T, Goitsuka R, Hascgawa A, Ohsugi Y, Taga T and Kishimoto T: Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur J Immunol 22: 1989-1993, 1992.
15. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liaytard J, Merlin M, Clement C, Morel-Fournier B, Lu ZY, Mannoni P, Sany J and Bataille R: Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78: 1988-1204, 1991.
16. Mihara M, Koishihara Y, Fukui H, Yasukawa K and Ohsugi, Y: Murine antihuman IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice. Immunology 74: 55-59, 1991.
17. Lu ZY, Brochier J, Wijdenes J, Brailly H, Bataille R and Klein B: High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol 22: 2819-2824, 1992.
18. Suzuki H, Takemura H, Yoshizaki K, Koishihara Y, Ohsugi Y, Okano A, Akiyama Y, Tojo T, Kishimoto T and Kashiwagi H: IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis. J Immunol 152: 935-942, 1994.
19. Hirata Y, Taga T, Hibi M, Nakano N, Hirano T and Kishimoto T: Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies. J Immunol 143: 2900-2906, 1989.
20. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T and Bendig MM: Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 53: 851-856, 1993.
21. Matsuda T, Hirano T and Kishimoto T: Establishment of an interleukin-6 (IL-6) / B cell stimulatory factor 2-dependent cell line and preparation of anti-IL-6 monoclonal antibodies. Eur J Immunol 18: 951-956, 1988.
22. Potter M and Kuff EL: Disorders in the differentiation of protein secretion in neoplastic plasma cells. J Mol Biol 9: 537-544, 1964.
23. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T and Bendig MM: Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions. Mol Immunol 31: 371381, 1994.
24. Okuno Y, Takahashi T, Suzuki A, Fukumoto M, Nakamura K, Fukui H, Koishihara Y, Ohsugi Y and Imura H: Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA. Exp Hematol 20: 395-400, 1992.
25. Ohsugi Y, Gershwin ME, Owens RB and Nelson-Rees WA: Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X-irradiated nude mice. J Natl Cancer Inst 65: 715-718, 1980.
26. Huang YW, Richardson JA, Tong AW, Zhang BQ, Stone MJ and Vitetta ES: Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res. 53: 1392-1396, 1993.
27. Urashima M, Chauhan D, Uchiyama H, Freeman GJ and Anderson KC: CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 85: 1903-1912, 1995.
28. Greipp PR, Raymond NM. Kyle RA and O'Fallon WM: Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 65: 305-310, 1985.
29. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H and Koehler G: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339-342, 1994.